647
T3D0646
Beryllium hydroxide
Beryllium hydroxide is a hydroxide of beryllium. Beryllium is a lightweight alkaline earth metal with the atomic number 4. It is a relatively rare element found naturally only combined with other elements in minerals. (L24)
13327-32-7
25879
BeH2O2
43.017660
White powder.
Decomposes at 1000°C.
300°C
Inhalation (L24)
Once in the body, beryllium acts as a hapten and interacts with human leucocyte antigen (HLA) DP presenting cells in the lungs, becoming physically associated with a major histocompatability (MHC) class II molecule. This MHC class II-beryllium-peptide complex is recognized by the T lymphocyte receptor, triggering CD4+ T lymphocyte activation and proliferation. The resulting inflammatory response is a cell-mediated process orchestrated by cytokines and results in the formation of (usually pulmonary) granulomas. Beryllium's toxicity may be controlled by the iron-storage protein ferritin, which sequesters beryllium by binding it and preventing it from interacting with other enzymes. (L25, A37, A91)
Beryllium is absorbed mainly through the lungs, where it enters the bloodstream and is transported throughout the body by binding to prealbumins and gamma-globulins. Beryllium accumulates in lung tissue and the skeleton. It is excreted mainly in the urine. (L25)
1, carcinogenic to humans. (L135)
Beryllium hydroxide is mainly used to produce beryllium metal and alloys (L974).
Chronic Oral: 0.002 mg/kg/day (L134)
Acute inhalation of a high level of beryllium can results in a pneumonia-like condition called acute beryllium disease. Chronic inhalation of beryllium can caused an inflammatory reaction in the respiratory system called chronic beryllium disease. Chronic beryllium disease may result in anorexia and weight loss, as well as right side heart enlargement and heart disease in advanced cases. Chronic exposure can also increase the risk of lung cancer. Skin contact with beryllium results in contact dermatitus. (L24, L25)
Chronic beryllium disease causes fatigue, weakness, difficulty breathing, and a persistent dry cough. (L24, L25)
Chronic beryllium disease is treated with immunosuppressive medicines, usually of the glucocorticoid class. (L24)
2009-03-21T01:08:19Z
2014-12-24T20:22:28Z
Transthyretin (P02766)
Ferritin light chain (P02792)
Ferritin heavy chain (P02794)
Ferritin, mitochondrial (Q8N4E7)
Ferritin heavy polypeptide-like 17 (Q9BXU8)
Putative ferritin heavy polypeptide-like 19 (P0C7X4)
(L25)
Beryllium_hydroxide
35102
C042156
Beryllium hydroxide
true
Transthyretin (P02766)
Ferritin light chain (P02792)
Ferritin heavy chain (P02794)
Ferritin, mitochondrial (Q8N4E7)
Ferritin heavy polypeptide-like 17 (Q9BXU8)
Putative ferritin heavy polypeptide-like 19 (P0C7X4)
(L25)
[Be++].[OH-].[OH-]
BeH2O2
InChI=1S/Be.2H2O/h;2*1H2/q+2;;/p-2
InChIKey=WPJWIROQQFWMMK-UHFFFAOYSA-L
43.0269
43.017661443
Exogenous
Solid